Home›Trial›NCT06376045

🔬NCT06376045Phase 2ACTIVE NOT RECRUITING

A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma

Study Summary

The primary objective of this study is to describe the efficacy of rocatinlimab in reducing asthma exacerbations.

Conditions

Interventions / Drugs

Rocatinlimab Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment317 participants

Primary Completion—

Lead SponsorAmgen

Data Retrieved2026-04-13 18:29:34.157167+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.